Brian O'Connell

Fear leads to bad decisions on a Wall Street trading floor, or at a high-stakes Vegas poker table.

In case you haven't heard, Jeffrey Kindler, Pfizer's general counsel, is replacing long-time CEO Henry "Hank" McKinnell as the new head of the company. There is a long-range strategy in naming a lawyer to run a drug company and I'll get to that in a moment.

When former Federal Reserve chairman Alan Greenspan's term in office expired on January 31, 2006, many people said, "There goes a legend." Maybe the better expression was, "Here comes the spin."

Buffett prefers to buy small, publicly traded companies with ample room for growth.

The top 10 Chinese companies in the biopharm sector account for only 20% of the market... leaving plenty of room for growth for Western companies.

The federal government plans to spend $3.3 billion on bird flu initiatives, about half of that on a vaccine.

Coming from Wall Street. I'm often asked what "professional" investors think about the life sciences industry.

The above statement reflects the opinion of a growing number of US governors and key state lawmakers.

Like a snowball rolling down Mt. Everest, stem- cell research was gaining momentum, not only in political and medical arenas, but on Wall Street, too.

How much of an impact does patent reform, real or imagined, have on biopharmaceutical stocks?